Removal of white cells (a type of immune cell) from blood before a transfusion and early surgical removal of the spleen may help protect patients with a genetic blood disease from developing autoimmune hemolytic anemia (AIHA), a condition where red blood cells are attacked by a person’s own immune…
Although rare, a new case report highlights that cold type autoimmune hemolytic anemia may be an early manifestation of systemic lupus erythematosus, researchers report. The study, “Cold agglutinin-induced hemolytic anemia as the primary presentation in SLE — A case report,” was published in the Journal of Family…
A small molecule targeting a protein of the complement system — a large group of plasma proteins that normally react with one another to fight infection — may help prevent the destruction of red blood cells that characterizes autoimmune hemolytic anemia (AIHA), a study suggests. The study “…
The case report of a patient with cold agglutinin disease (CAD) who developed chronic inflammation of the gums (periodontitis) highlights the need for dentists to be aware of CAD signs and symptoms. The study, “Cold agglutinin disease and its implications for dental treatment,” was published in the journal…
A case study detailing the treatment of an 84-year-old man who developed B-cell prolymphocytic leukemia and cold type autoimmune hemolytic anemia (AIHA) suggests possible “innovative” therapies for these rare diseases. The study, a letter to the editor titled “Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic…
A rare case of a patient with cold agglutinin disease (CAD) who developed a blood cancer called multiple myeloma was recently reported by researchers in Norway. Although both conditions are linked to malfunctioning of B-cells, in this case, clinicians believe the patient developed the two disorders independent of each…
Cold agglutinin disease (CAD) patients who relapse after standard treatment could benefit from a short-term course of treatment with bortezomib, an approved therapy for certain cancers, a Phase 2 clinical trial shows. Trial findings were published in the study, “Short course of Bortezomib in anemic patients with relapsed cold…
Sutimlimab, an antibody against complement C1, increases hemoglobin levels in patients with cold agglutinin disease and prevents blood transfusions, a first-in-human trial shows. The study, “Inhibition of Complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial” was published in the journal Blood. Autoimmune…
Get regular updates to your inbox.